Tumor necrosis factor receptor 2: Its contribution to acute cellular rejection and clear cell renal carcinoma

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Wang, Jun ^a   Al Lamki, Rafia S ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CONFORMATIONAL TRANSITION; DELAYED GRAFT FUNCTION; DNA POLYMORPHISM; DRUG TARGETING; ENDOTHELIUM CELL; GRAFT SURVIVAL; HUMAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TISSUE INJURY; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; GRAFT REJECTION; KIDNEY TUMOR; METABOLISM;

ANIMALS; CARCINOMA, RENAL CELL; GRAFT REJECTION; HUMANS; KIDNEY NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II;

EID: 84890104009     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/821310     Document Type: Review

References (99)

1. Hehlgans T., Pfeffer K., The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005 115 1 1 20 2-s2.0-17944371991 10.1111/j.1365-2567.2005. 02143.x (Pubitemid 40598088)
2. Kriegler M., Perez C., DeFay K., Albert I., Lu S. D., A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988 53 1 45 53 2-s2.0-0024281428
3. Fiers W., Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Letters 1991 285 2 199 212 2-s2.0-0025884625 10.1016/0014-5793(91)80803-B
4. Rothe J., Gehr G., Loetscher H., Lesslauer W., Tumor necrosis factor receptors-structure and function. Immunologic Research 1992 11 2 81 90 2-s2.0-0026673687
5. Vandenabeele P., Declercq W., Vercammen D., van de Craen M., Grooten J., Loetscher H., Brockhaus M., Lesslauer W., Fiers W., Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. Journal of Experimental Medicine 1992 176 4 1015 1024 2-s2.0-0026768768
6. Aggarwal B. B., Signalling pathways of the TNF superfamily: a double-edged sword. Nature Reviews Immunology 2003 3 9 745 756 2-s2.0-0141465062 10.1038/nril184 (Pubitemid 41070815)
7. Bradley J. R., Thiru S., Pober J. S., Disparate localization of 55-kd and 75-kd tumor necrosis factor receptors in human endothelial cells. American Journal of Pathology 1995 146 1 27 32 2-s2.0-0028859734
8. Al-Lamki R. S., Wang J., Skepper J. N., Thiru S., Pober J. S., Bradley J. R., Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Laboratory Investigation 2001 81 11 1503 1515 2-s2.0-0035161063 (Pubitemid 33064276)
9. Tartaglia L. A., Goeddel D. V., Reynolds C., Figari I. S., Weber R. F., Fendly B. M., Palladino M. A. Jr., Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. Journal of Immunology 1993 151 9 4637 4641 2-s2.0-0027521134 (Pubitemid 23318517)
10. Al-Lamki R. S., Brookes A. P., Wang J., Reid M. J., Parameshwar J., Goddard M. J., Tellides G., Wan T., Min W., Pober J. S., Bradley J. R., TNF receptors differentially signal and are differentially expressed and regulated in the human heart. American Journal of Transplantation 2009 9 12 2679 2696 2-s2.0-72449129490 10.1111/j.1600-6143.2009.02831.x
11. Kelly M. L., Wang M., Crisostomo P. R., Abarbanell A. M., Herrmann J. L., Weil B. R., Meldrum D. R., TNF receptor 2, not TNF receptor 1, enhances mesenchymal stem cell-mediated cardiac protection following acute ischemia. Shock 2010 33 6 602 607 2-s2.0-77952365320 10.1097/SHK.0b013e3181cc0913
12. Al-Lamki R. S., Lu W., Wang J., Yang J., Sargeant T. J., Wells R., Suo C., Wright P., Goddard M., Huang Q., TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-kit cardiac stem cells in ischemic heart disease. Stem Cells 2013 31 9 1881 1892 10.1002/stem.1433
13. Montgomery S. L., Mastrangelo M. A., Habib D., Narrow W. C., Knowlden S. A., Wright T. W., Bowers W. J., Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF- α suppressive therapeutic strategies in the brain. American Journal of Pathology 2011 179 4 2053 2070 2-s2.0-80053268668 10.1016/j.ajpath.2011.07.001
14. Patel J. R., Williams J. L., Muccigrosso M. M., Liu L., Sun T., Rubin J. B., Klein R. S., Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathologica 2012 124 6 847 860
15. Tartaglia L. A., Weber R. F., Figari I. S., Reynolds C., Palladino M. A. Jr., Goeddel D. V., The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proceedings of the National Academy of Sciences of the United States of America 1991 88 20 9292 9296 2-s2.0-0026072837 (Pubitemid 21915617)
16. Al-Lamki R. S., Sadler T. J., Wang J., Reid M. J., Warren A. Y., Movassagh M., Lu W., Mills I. G., Neal D. E., Burge J., Vandenebeele P., Pober J. S., Bradley J. R., Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. American Journal of Pathology 2010 177 2 943 954 2-s2.0-77957257787 10.2353/ajpath.2010.091218
17. Depuydt B., van Loo G., Vandenabeele P., Declercq W., Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors. Journal of Cell Science 2005 118 3 497 504 2-s2.0-14644414800 10.1242/jcs.01640 (Pubitemid 40310117)
18. Al-Lamki R. S., Wang J., Vandenabeele P., Bradley J. A., Thiru S., Luo D., Min W., Pober J. S., Bradley J. R., TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. The FASEB Journal 2005 19 12 1637 1645 2-s2.0-26444575419 10.1096/fj.05-3841com (Pubitemid 41429521)
19. Grell M., Becke F. M., Wajant H., Mannel D. N., Scheurich P., TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. European Journal of Immunology 1998 28 1 257 263 (Pubitemid 28048296)
20. Chen X., Oppenheim J. J., TNF- α: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Current Directions in Autoimmunity 2010 11 119 134 2-s2.0-77949483150 10.1159/000289201
21. Chen X., Oppenheim J. J., The phenotypic and functional consequences of tumour necrosis factor receptor type 2 expression on CD4+FoxP3+ regulatory T cells. Immunology 2011 133 4 426 433 2-s2.0-79959902280 10.1111/j.1365-2567. 2011.03460.x
22. Meier-Kriesche H.-U., Schold J. D., Srinivas T. R., Kaplan B., Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of Transplantation 2004 4 3 378 383 2-s2.0-1442338509 10.1111/j.1600-6143.2004.00332.x (Pubitemid 38282293)
23. Morel D., Normand E., Lemoine C., Merlio J.-P., Velours J., Astier T., Bonnet F., Aparicio M., Potaux L., Bloch B., Tumor necrosis factor alpha in human kidney transplant rejection-analysis by in situ hybridization. Transplantation 1993 55 4 773 777 2-s2.0-0027522467 (Pubitemid 23122045)
24. Mulders P. F. A., Renal cell carcinoma. World Journal of Urology 2008 26 2 113 2-s2.0-42349117281 10.1007/s00345-008-0248-1
25. Cohen H. T., McGovern F. J., Renal-cell carcinoma. The New England Journal of Medicine 2005 353 23 2477 2490 2-s2.0-28844484134 10.1056/NEJMra043172 (Pubitemid 41770167)
26. Berger A., Brandina R., Atalla M. A., Herati A. S., Kamoi K., Aron M., Haber G.-P., Stein R. J., Desai M. M., Kavoussi L. R., Gill I. S., Laparoscopic radical nephrectomy for renal cell carcinoma: oncological outcomes at 10 years or more. Journal of Urology 2009 182 5 2172 2176 2-s2.0-70350440098 10.1016/j.juro.2009.07.047
27. Janzen N. K., Kim H. L., Figlin R. A., Belldegrun A. S., Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. The Urologic Clinics of North America 2003 30 4 843 852 2-s2.0-0344442746 10.1016/S0094-0143(03)00056-9 (Pubitemid 37485197)
28. Piselli P., Serraino D., Segoloni G. P., Sandrini S., Piredda G. B., Scolari M. P., Rigotti P., Busnach G., Messa P., Donati D., Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. European Journal of Cancer 2013 49 2 336 344
29. Rocha A., Malheiro J., Fonseca I., Martins L. S., Dias L., Almeida M., Pedroso S., Henriques A. C., Noncutaneous neoplasms after kidney transplantation: analysis at single center. Transplantation Proceedings 2013 45 3 1102 1105
30. Tuzuner A., Cakir F., Akyol C., Celebi Z. K., Ceylaner S., Ceylaner G., Sengul S., Keven K., Nephron-sparing surgery for renal cell carcinoma of the allograft after renal transplantation: report of two cases. Transplantation Proceedings 2013 45 3 958 960
31. Tartaglia L. A., Pennica D., Goeddel D. V., Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. The Journal of Biological Chemistry 1993 268 25 18542 18548 2-s2.0-0027301244 (Pubitemid 23273787)
32. Ledgerwood E. C., Pober J. S., Bradley J. R., Recent advances in the molecular basis of TNF signal transduction. Laboratory Investigation 1999 79 9 1041 1050 2-s2.0-0032854069 (Pubitemid 29444534)
33. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., Scheurich P., Schmid J. A., Wajant H., Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. Journal of Cell Science 2002 115, part 13 2757 2770 (Pubitemid 34846516)
34. Rothe M., Sarma V., Dixit V. M., Goeddel D. V., TRAF2-Mediated activation of NF- B by TNF receptor 2 and CD40. Science 1995 269 5229 1424 1427 2-s2.0-0028978626
35. Zhao Y., Conze D. B., Hanover J. A., Ashwell J. D., Tumor necrosis factor receptor 2 signaling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signaling. The Journal of Biological Chemistry 2007 282 11 7777 7782 2-s2.0-34247191196 10.1074/jbc.M609146200 (Pubitemid 47093598)
36. Ji W., Li Y., Wan T., Wang J., Zhang H., Chen H., Min W., Both internalization and AIP1 association are required for tumor necrosis factor receptor 2-mediated JNK signaling. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2271 2279
37. Karin M., The regulation of AP-1 activity by mitogen-activated protein kinases. Philosophical Transactions of the Royal Society B 1996 351 1336 127 134 2-s2.0-0030605403 (Pubitemid 126745321)
38. Haridas V., Darnay B. G., Natarajan K., Heller R., Aggarwal B. B., Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor- B activation, and c-Jun kinase activation. Journal of Immunology 1998 160 7 3152 3162 2-s2.0-0032055981 (Pubitemid 28164703)
39. Jupp O. J., McFarlane S. M., Anderson H. M., Littlejohn A. F., Mohamed A. A. A., MacKay R. H., Vandenabeele P., MacEwan D. J., Type II tumour necrosis factor- α receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochemical Journal 2001 359, part 3 525 535 2-s2.0-0035504199 10.1042/0264-6021:3590525 (Pubitemid 33063376)
40. Grech A. P., Gardam S., Chan T., Quinn R., Gonzales E., Basten A., Brink R., Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. The Journal of Biological Chemistry 2005 280 36 31572 31581 2-s2.0-24744440776 10.1074/jbc.M504849200 (Pubitemid 41291901)
41. Rothe M., Wong S. C., Henzel W. J., Goeddel D. V., A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994 78 4 681 692 2-s2.0-0028124428 10.1016/0092-8674(94)90532-0 (Pubitemid 24268590)
42. Pimentel-Muiños F. X., Seed B., Regulated commitment of TNF receptor signaling: a molecular switch for death or activation. Immunity 1999 11 6 783 793 2-s2.0-0033452005 (Pubitemid 30030717)
43. Mak T. W., Yeh W. C., Signaling for survival and apoptosis in the immune system. Arthritis Research 2002 4 supplement 3 243 252
44. Bruggeman L. A., Drawz P. E., Kahoud N., Lin K., Barisoni L., Nelson P. J., TNFR2 interposes the proliferative and NF-B-mediated inflammatory response by podocytes to TNF- α Laboratory Investigation 2011 91 3 413 425 2-s2.0-79952087898 10.1038/labinvest.2010.199
45. Li J. H., Pober J. S., The cathepsin B death pathway contributes to TNF plus INF- γ -mediated human endothelial injury. Journal of Immunology 2005 175 3 1858 1866 2-s2.0-22544442744 (Pubitemid 41023092)
46. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G., Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews Molecular Cell Biology 2010 11 10 700 714 2-s2.0-77957105977 10.1038/nrm2970
47. Pan S., An P., Zhang R., He X., Yin G., Min W., Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Molecular and Cellular Biology 2002 22 21 7512 7523 2-s2.0-0036838086 10.1128/MCB.22.21.7512-7523.2002
48. Hummel M., Kurian S. M., Lin S., Borodyanskiy A., Zhang Z., Li Z., Kim S. J., Salomon D. R., Abecassis M., Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 2009 87 2 178 188 2-s2.0-59649108625 10.1097/TP.0b013e3181938971
49. Dhaouadi T., Sfar I., Bardi R., Jendoubi-Ayed S., Abdallah T. B., Ayed K., Gorgi Y., Cytokine gene polymorphisms in kidney transplantation. Transplantation Proceedings 2013 45 6 2152 2157
50. Wramner L. G., Norrby J., Hahn-Zoric M., Ahlmén J., Börjesson P.-A., Carlström J., Hytönen A.-M., Olausson M., Hanson L. Å., Padyukov L., Impaired kidney graft survival is associated with the TNF- α genotype. Transplantation 2004 78 1 117 121 2-s2.0-20844449072 10.1097/01.TP.0000134768.82277.CB (Pubitemid 38938294)
51. Dmitrienko S., Hoar D. I., Balshaw R., Keown P. A., Immune response gene polymorphisms in renal transplant recipients. Transplantation 2005 80 12 1773 1782 2-s2.0-30144434975 10.1097/01.tp.0000184624.54005.9f (Pubitemid 43054004)
52. Reinhold S. W., Straub R. H., Krüger B., Kaess B., Bergler T., Weingart C., Banas M. C., Krämer B. K., Banas B., Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation. Cytokine 2012 57 3 379 388 2-s2.0-84856395843 10.1016/j.cyto.2011.12.006
53. Hoffmann U., Bergler T., Rihm M., Pace C., Krüger B., Rümmele P., Stoelcker B., Banas B., Männel D. N., Krämer B. K., Upregulation of TNF receptor type 2 in human and experimental renal allograft rejection. American Journal of Transplantation 2009 9 4 675 686 2-s2.0-63349097485 10.1111/j.1600-6143.2008.02536.x
54. Santee S. M., Owen-Schaub L. B., Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. The Journal of Biological Chemistry 1996 271 35 21151 21159 2-s2.0-0029830141 10.1074/jbc.271.35.21151 (Pubitemid 26292967)
55. Ramesh G., Reeves W. B., Inflammatory cytokines in acute renal failure. Kidney International, Supplement 2004 66 91 S56 S61 2-s2.0-4644324913 (Pubitemid 39281716)
56. Al-Lamki R. S., Wang J., Tolkovsky A. M., Bradley J. A., Griffin J. L., Thiru S., Wang E. C. Y., Bolton E., Min W., Moore P., Pober J. S., Bradley J. R., TL1A both promotes and protects from renal inflammation and injury. Journal of the American Society of Nephrology 2008 19 5 953 960 2-s2.0-44049085188 10.1681/ASN.2007060706
57. Puga I., Lainez B., Fernández-Real J. M., Buxadé M., Broch M., Vendrell J., Espel E., A polymorphism in the 3′ untranslated region of the gene for tumor necrosis factor receptor 2 modulates reporter gene expression. Endocrinology 2005 146 5 2210 2220 2-s2.0-17744395754 10.1210/en.2004-1366 (Pubitemid 40577508)
58. Uribe-Herranz M., Casinghino S. R., Bosch-Presegué L., Fodor W. L., Costa C., Identification of soluble and membrane-bound isoforms of porcine tumor necrosis factor receptor 2. Xenotransplantation 2011 18 2 131 146 2-s2.0-79955040833 10.1111/j.1399-3089.2011.00634.x
59. Sabatine M. S., Laufer T., Glimcher L. H., Widmer M., Winn H., Auchincloss H. Jr., Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts. Transplantation 1998 65 1 113 120 2-s2.0-0031886022 10.1097/00007890-199801150-00022 (Pubitemid 28100442)
60. van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F., Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America 1992 89 11 4845 4849 2-s2.0-0026741275 10.1073/pnas.89.11.4845
61. Bruneau S., Woda C. B., Daly K. P., Boneschansker L., Jain N. G., Kochupurakkal N., Contreras A. G., Seto T., Briscoe D. M., Key features of the intragraft microenvironment that determine long-term survival following transplantation. Frontiers in Immunology 2012 3, article 54
62. Burton C. J., Combe C., Walls J., Harris K. P. G., Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrology Dialysis Transplantation 1999 14 11 2628 2633 2-s2.0-0033281525 (Pubitemid 32208377)
63. Robertson H., Wheeler J., Morley A. R., Booth T. A., Talbot D., Kirby J. A., β -chemokine expression and distribution in paraffin-embedded transplant renal biopsy sections: analysis by scanning laser confocal microscopy. Histochemistry and Cell Biology 1998 110 2 207 213 2-s2.0-0031822611 10.1007/s004180050283 (Pubitemid 28348376)
64. Thorburn E., Kolesar L., Brabcova E., Petrickova K., Petricek M., Jaresova M., Slavcev A., Striz I., CXC and CC chemokines induced in human renal epithelial cells by inflammatory cytokines. APMIS 2009 117 7 477 487 2-s2.0-67651171494 10.1111/j.1600-0463.2009.02446.x
65. Wang J., Li Z., Al-Lamki R., Wang J., Zuo N., Bradley J. R., Wang L., The role of tumor necrosis factor- α converting enzyme in renal transplant rejection. American Journal of Nephrology 2010 32 4 362 368 2-s2.0-77956790711 10.1159/000320467
66. Adrain C., Zettl M., Christova Y., Taylor N., Freeman M., Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 2012 335 6065 225 228 2-s2.0-84855822415 10.1126/science.1214400
67. Diller R., Winde G., Kötting S., Senninger N., Dietl K.-H., Spiegel H.-U., sTNF-RII: is it useful for the early diagnosis of rejection and for prognosis after renal transplantation? Transplant International 2002 15 7 335 340 2-s2.0-0036933561 10.1111/j.1432-2277.2002.tb00175.x (Pubitemid 36068186)
68. Migone T.-S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., Hong J. S., Perry J. W., Chen S.-F., Zhou J. X. H., Cho Y. H., Ullrich S., Kanakaraj P., Carrell J., Boyd E., Olsen H. S., Hu G., Pukac L., Liu D., Ni J., Kim S., Gentz R., Feng P., Moore P. A., Ruben S. M., Wei P., TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002 16 3 479 492 2-s2.0-18344385475 10.1016/S1074-7613(02)00283-2 (Pubitemid 34260924)
69. Lopez J. I., Renal tumors with clear cells. A review. Pathology, Research and Practice 2013 209 3 137 146
70. Sethi G., Sung B., Aggarwal B. B., TNF: a master switch for inflammation to cancer. Frontiers in Bioscience 2008 13 13 5094 5107 2-s2.0-42649124339 10.2741/3066 (Pubitemid 351599660)
71. Aggarwal B. B., Shishodia S., Sandur S. K., Pandey M. K., Sethi G., Inflammation and cancer: how hot is the link? Biochemical Pharmacology 2006 72 11 1605 1621 2-s2.0-33750497844 10.1016/j.bcp.2006.06.029 (Pubitemid 44666739)
72. Balkwill F., TNF- α in promotion and progression of cancer. Cancer and Metastasis Reviews 2006 25 3 409 416 2-s2.0-33845524008 10.1007/s10555-006- 9005-3 (Pubitemid 44922358)
73. Balkwill F., Tumor necrosis factor or tumor promoting factor? Cytokine and Growth Factor Reviews 2002 13 2 135 141 2-s2.0-0036005888 10.1016/S1359-6101(01)00020-X (Pubitemid 34229388)
74. Chuang M.-J., Sun K.-H., Tang S.-J., Deng M.-W., Wu Y.-H., Sung J.-S., Cha T.-L., Sun G.-H., Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Science 2008 99 5 905 913 2-s2.0-43249107158 10.1111/j.1349-7006.2008. 00756.x (Pubitemid 351997592)
75. Baştürk B., Yavaşçaolu I., Vuruşkan H., Göral G., Oktay B., Oral H. B., Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 2005 30 1 41 45 2-s2.0-15244357265 10.1016/j.cyto.2004.10.016 (Pubitemid 40387354)
76. Einollahi B., Malignancy after kidney transplantation. Annals of Transplantation 2012 17 1 145 146 2-s2.0-84859385029
77. Aaltomaa S., Lipponen P., Ala-Opas M., Eskelinen M., Syrjanen K., Prognostic value of Ki-67 expression in renal cell carcinomas. European Urology 1997 31 3 350 355 2-s2.0-0030951924 (Pubitemid 27156389)
78. Weber T., Meinhardt M., Zastrow S., Wienke A., Fuessel S., Wirth M. P., Immunohistochemical analysis of prognostic protein markers for primary localized clear cell renal cell carcinoma. Cancer Investigation 2013 31 1 51 59
79. Ikemoto S., Narita K., Yoshida N., Wada S., Kishimoto T., Sugimura K., Nakatani T., Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncology Reports 2003 10 6 1947 1955 2-s2.0-2642517397
80. Grell M., Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. Journal of Inflammation 1995 47 1-2 8 17 2-s2.0-0029551303 (Pubitemid 26376197)
81. Qi H., Ohh M., The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor- B-dependent antiapoptotic pathway. Cancer Research 2003 63 21 7076 7080 2-s2.0-0242694963 (Pubitemid 37413442)
82. Al-Ansari A. S., Ollier W. E. R., Villarreal J., Ordi J., Teh L.-S., Hajeer A. H., Tumor necrosis factor receptor II (TNFRII) exon 6 polymorphism in systemic lupus erythematosus. Tissue Antigens 2000 55 1 97 99 2-s2.0-0033980452 10.1034/j.1399-0039.2000.550122.x (Pubitemid 30072711)
83. Guan X., Liao Z., Ma H., Qian J., Liu Z., Yuan X., Gomez D., Komaki R., Wang L.-E., Wei Q., TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 2011 11, article no. 447 2-s2.0-80053980947 10.1186/1471-2407-11-447
84. Horiuchi T., Kiyohara C., Tsukamoto H., Sawabe T., Furugo I., Yoshizawa S., Ueda A., Tada Y., Nakamura T., Kimoto Y., Mitoma H., Harashima S., Yoshizawa S., Shimoda T., Okamura S., Nagasawa K., Harada M., A functional M196R polymorphism of tumour necrosis factor receptor type 2 is associated with systemic lupus erythematosus: a case-control study and a meta-analysis. Annals of the Rheumatic Diseases 2007 66 3 320 324 2-s2.0-34147198192 10.1136/ard.2006.058917 (Pubitemid 46579631)
85. Mestiri S., Bouaouina N., Ahmed S. B., Chouchane L., A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine 2005 30 4 182 187 2-s2.0-18144365537 10.1016/j.cyto.2005.01.007 (Pubitemid 40615966)
86. Till A., Rosenstiel P., Krippner-Heidenreich A., Mascheretti-Croucher S., Croucher P. J. P., Schäfer H., Scheurich P., Seegert D., Schreiber S., The Met-196 → Arg variation of human Tumor Necrosis Factor Receptor 2 (TNFR2) affects TNF- α -induced apoptosis by impaired NF- B signaling and target gene expression. The Journal of Biological Chemistry 2005 280 7 5994 6004 2-s2.0-14044273722 10.1074/jbc.M411541200 (Pubitemid 40280083)
87. Baer P. C., Bereiter-Hahn J., Missler C., Brzoska M., Schubert R., Gauer S., Geiger H., Conditioned medium from renal tubular epithelial cells initiates differentiation of human mesenchymal stem cells. Cell Proliferation 2009 42 1 29 37 2-s2.0-58449131654 10.1111/j.1365-2184.2008.00572.x
88. Sasi S. P., Yan X., Enderling H., Breaking the "harmony" of TNF-alpha signaling for cancer treatment. Oncogene 2012 31 37 4117 4127
89. Kemper O., Derre J., Cherif D., Engelmann H., Wallach D., Berger R., The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Human Genetics 1991 87 5 623 624 2-s2.0-0025946360
90. Reeves B. R., Pickup V. L., The chromosome changes in non-Burkitt lymphomas. Human Genetics 1980 53 3 349 355 2-s2.0-0018897606 (Pubitemid 10103063)
91. Benucci M., Saviola G., Manfredi M., Sarzi-Puttini P., Atzeni F., Tumor necrosis factors blocking agents: analogies and differences. Acta Bio-Medica 2012 83 1 72 80
92. Joyau C., Veyrac G., Dixneuf V., Jolliet P., Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clinical and experimental rheumatology. 2012 30 5 700 706
93. Wiens A., Venson R., Correr C. J., Otuki M. F., Pontarolo R., Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010 30 4 339 353 2-s2.0-77950411921 10.1592/phco.30.4.339
94. Javed Q., Murtaza I., Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. Heart, Lung & Circulation 2013 22 5 323 327
95. Pascher A., Klupp J., Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNF α inhibitors? BioDrugs 2005 19 4 211 231 2-s2.0-26444549350 10.2165/00063030-200519040-00002 (Pubitemid 41430157)
96. Scallon B., Cai A., Solowski N., Rosenberg A., Song X.-Y., Shealy D., Wagner C., Binding and functional comparisons of two types of tumor necrosis factor antagonists. Journal of Pharmacology and Experimental Therapeutics 2002 301 2 418 426 2-s2.0-0036229932 10.1124/jpet.301.2.418 (Pubitemid 34429950)
97. Grell M., Douni E., Wajant H., Lohden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., Scheurich P. S., The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995 83 5 793 802 2-s2.0-0028866022
98. Ban L., Zhang J., Wang L., Kuhtreiber W., Burger D., Faustman D. L., Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proceedings of the National Academy of Sciences of the United States of America 2008 105 36 13644 13649 2-s2.0-51649084550 10.1073/pnas.0803429105
99. Welborn M. B. III, van Zee K., Edwards P. D., Pruitt J. H., Kaibara A., Vauthey J.-N., Rogy M., Castleman W. L., Lowry S. F., Kenney J. S., Stüber D., Ettlin U., Wipf B., Loetscher H., Copeland E. M. III, Lesslauer W., Moldawer L. L., A human tumor necrosis factor p75 receptor agonist stimulates in vitro T cell proliferation but does not produce inflammation or shock in the baboon. Journal of Experimental Medicine 1996 184 1 165 171 2-s2.0-8944220717 10.1084/jem.184.1.165 (Pubitemid 26247226)